These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

810 related articles for article (PubMed ID: 29569427)

  • 1. Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
    Kim YG; Jeon JY; Han SJ; Kim DJ; Lee KW; Kim HJ
    Diabetes Obes Metab; 2018 Aug; 20(8):1852-1858. PubMed ID: 29569427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
    Kim YG; Han SJ; Kim DJ; Lee KW; Kim HJ
    Cardiovasc Diabetol; 2018 Jun; 17(1):91. PubMed ID: 29935543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A nationwide population-based study.
    Han SJ; Ha KH; Lee N; Kim DJ
    Diabetes Obes Metab; 2021 Mar; 23(3):682-691. PubMed ID: 33236515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors and the risk of heart failure: A nationwide cohort study of older adults with diabetes mellitus.
    Fralick M; Colacci M; Thiruchelvam D; Gomes T; Redelmeier DA
    Diabetes Obes Metab; 2021 Apr; 23(4):950-960. PubMed ID: 33336894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis : A Multicenter Cohort Study.
    Douros A; Lix LM; Fralick M; Dell'Aniello S; Shah BR; Ronksley PE; Tremblay É; Hu N; Alessi-Severini S; Fisher A; Bugden SC; Ernst P; Filion KB;
    Ann Intern Med; 2020 Sep; 173(6):417-425. PubMed ID: 32716707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes.
    Dawwas GK; Smith SM; Park H
    Diabetes Obes Metab; 2019 Jan; 21(1):28-36. PubMed ID: 30039524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Dipeptidyl Peptidase 4 Inhibitors and Sulfonylureas on the Risk of Diabetic Ketoacidosis.
    Dawwas GK; Flory JH; Hennessy S; Leonard CE; Lewis JD
    Diabetes Care; 2022 Apr; 45(4):919-927. PubMed ID: 35147696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases.
    Wang L; Voss EA; Weaver J; Hester L; Yuan Z; DeFalco F; Schuemie MJ; Ryan PB; Sun D; Freedman A; Alba M; Lind J; Meininger G; Berlin JA; Rosenthal N
    Pharmacoepidemiol Drug Saf; 2019 Dec; 28(12):1620-1628. PubMed ID: 31456304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA1c Levels.
    D'Andrea E; Wexler DJ; Kim SC; Paik JM; Alt E; Patorno E
    JAMA Intern Med; 2023 Mar; 183(3):242-254. PubMed ID: 36745425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study.
    Seong JM; Kim JJ; Kim HJ; Sohn HS
    Cardiovasc Diabetol; 2020 Jun; 19(1):95. PubMed ID: 32571319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On-label use of sodium-glucose cotransporter 2 inhibitors might increase the risk of diabetic ketoacidosis in patients with type 1 diabetes.
    Horii T; Oikawa Y; Atsuda K; Shimada A
    J Diabetes Investig; 2021 Sep; 12(9):1586-1593. PubMed ID: 33448127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of sodium glucose co-transporter-2 inhibitors with risk of diabetic ketoacidosis among hospitalized patients: A multicentre cohort study.
    Sarma S; Hodzic-Santor B; Raissi A; Colacci M; Verma AA; Razak F; Højbjerg Lassen MC; Fralick M
    J Diabetes Complications; 2024 Sep; 38(9):108827. PubMed ID: 39096768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The associations of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as add-on to metformin with fracture risk in patients with type 2 diabetes mellitus.
    van Hulten V; Driessen JHM; Starup-Linde JK; Al-Mashhadi ZK; Viggers R; Klungel OH; Souverein PC; Vestergaard P; Stehouwer CDA; van den Bergh JP
    Diabetes Obes Metab; 2023 Nov; 25(11):3235-3247. PubMed ID: 37503747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Liu J; Li L; Li S; Wang Y; Qin X; Deng K; Liu Y; Zou K; Sun X
    Diabetes Obes Metab; 2020 Sep; 22(9):1619-1627. PubMed ID: 32364674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study.
    Kohsaka S; Lam CSP; Kim DJ; Cavender MA; Norhammar A; Jørgensen ME; Birkeland KI; Holl RW; Franch-Nadal J; Tangri N; Shaw JE; Ilomäki J; Karasik A; Goh SY; Chiang CE; Thuresson M; Chen H; Wittbrodt E; Bodegård J; Surmont F; Fenici P; Kosiborod M;
    Lancet Diabetes Endocrinol; 2020 Jul; 8(7):606-615. PubMed ID: 32559476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Below-Knee Amputation: A Multicenter Observational Study.
    Yu OHY; Dell'Aniello S; Shah BR; Brunetti VC; Daigle JM; Fralick M; Douros A; Hu N; Alessi-Severini S; Fisher A; Bugden SC; Ronksley PE; Filion KB; Ernst P; Lix LM;
    Diabetes Care; 2020 Oct; 43(10):2444-2452. PubMed ID: 32759360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-glucose cotransporter-2 inhibitors and the risk of urinary tract infection among diabetic patients in Japan: Target trial emulation using a nationwide administrative claims database.
    Takeuchi Y; Kumamaru H; Hagiwara Y; Matsui H; Yasunaga H; Miyata H; Matsuyama Y
    Diabetes Obes Metab; 2021 Jun; 23(6):1379-1388. PubMed ID: 33606891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying Risk Factors for Diabetic Ketoacidosis Associated with SGLT2 Inhibitors: a Nationwide Cohort Study in the USA.
    Fralick M; Redelmeier DA; Patorno E; Franklin JM; Razak F; Gomes T; Schneeweiss S
    J Gen Intern Med; 2021 Sep; 36(9):2601-2607. PubMed ID: 33564942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SGLT2 Inhibitors and the Risk of Acute Kidney Injury in Older Adults With Type 2 Diabetes.
    Zhuo M; Paik JM; Wexler DJ; Bonventre JV; Kim SC; Patorno E
    Am J Kidney Dis; 2022 Jun; 79(6):858-867.e1. PubMed ID: 34762974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.